Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) reported that the first three patients treated under a modified Phase 2 protocol for its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE